Genetic alterations in hepatocellular carcinomas: Associations with clinical parameters;Alterations génétiques associées aux carcinomes hépatocellulaires: Corrélations avec les paramètres anatomo-cliniques

Gastroenterologie Clinique et Biologique

Volumn 25, Issue 12, 2001, Pages 1067-1077

  Bluteau, Olivier ^a   Laurent Puig, Pierre ^a   Zucman Rossi, Jessica ^a  

^a INSERM   (France)

Author keywords

catenin; Axin; Carcinogenesis; Chromosome; Hepatocellular carcinoma; Loss of heterozygosity; Mutation; Oncogene; P53; Tumor suppressor gene

Indexed keywords

AXIN; BETA CATENIN; PROTEIN P16; PROTEIN P53; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN; AXIN PROTEIN; CTNNB1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; JAK3 PROTEIN, HUMAN; JANUS KINASE 3; ONCOPROTEIN; PROTEIN; PROTEIN TYROSINE KINASE; REPRESSOR PROTEIN; TRANSACTIVATOR PROTEIN; ZEBRAFISH PROTEIN;

CANCER GENETICS; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CHROMOSOME LOSS; CLINICAL FEATURE; GENE AMPLIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HETEROZYGOSITY LOSS; HISTOLOGY; LIVER CELL CARCINOMA; ONCOGENE MYC; ONCOGENE N RAS; REVIEW; RISK FACTOR; TUMOR SUPPRESSOR GENE; CHROMOSOME ABERRATION; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENETICS; HUMAN; LIVER TUMOR; MUTATION; SIGNAL TRANSDUCTION;

BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CHROMOSOME ABERRATIONS; CYTOSKELETAL PROTEINS; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENES, MYC; GENES, P16; GENES, P53; HUMANS; JANUS KINASE 3; LIVER NEOPLASMS; MUTATION; PROTEIN-TYROSINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; WNT PROTEINS; ZEBRAFISH PROTEINS;

EID: 0035544198     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (146)

1. Increase in primary liver cancer in the UK, 1979-94
2. Trends in primary liver cancer
3. Rising incidence of hepatocellular carcinoma in the United States
4. Hepatocellular carcinoma
5. Clinical, pathologic, and etiologic heterogeneity in hepatocellular carcinoma: Evidence from Southern Africa
6. Risk factors for hepatocellular carcinoma among patients with chronic liver disease
7. Histological features and clinical course of large regenerative nodules: Evaluation of their precancerous potentiality
8. Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: A prospective study
9. Macroregenerative nodules in cirrhosis are not associated with elevated serum or stainable tissue alpha-fetoprotein
10. Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis
11. Clonal analysis of macronodules in cirrhosis
12. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma
13. Macroregenerative nodule of the liver. A clinicopathologic study of 345 autopsy cases of chronic liver disease
14. Prevalence of liver cell dysplasia and association with HCC in a series of 100 cirrhotic liver explants
15. Hepatocellular carcinoma occurring in nonfibrotic liver: Epidemiologic and histopathologic analysis of 80 French cases
16. Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma
17. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma
18. Insertional activation of mevalonate kinase by hepatitis B virus DNA in a human hepatoma cell line
19. Hepatitis B virus-related insertional mutagenesis implicates SERCA1 gene in the control of apoptosis
20. Transcriptional trans-activating function of hepatitis B virus
21. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene
22. X-gene product of hepatitis B virus induces apoptosis in liver cells
23. The chemistry and biology of aflatoxin B(1): From mutational spectrometry to carcinogenesis
24. DNA analysis of hepatocellular carcinoma and clinicopathologic implications
25. Prediction of relapse or survival after resection in human hepatomas by DNA flow cytometry
26. Flow cytometric DNA analysis of hepatocellular carcinoma
27. Flow cytometric DNA analysis of hepatocellular carcinoma: Preliminary report
28. Liver cell dysplasia: A DNA aneuploid lesion with distinct morphologic features
29. Abnormalities of chromosome 1 and loss of heterozygosity on 1p in primary hepatomas
30. Allelotype study of primary hepatocellular carcinoma
31. Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinomas
32. Frequent loss of heterozygosity on chromosome 22 in hepatocellular carcinoma
33. Allelotype and loss of heterozygosity of p53 in primary and recurrent hepatocellular carcinomas. A study of 150 patients
34. p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan
35. Allelic loss at chromosome band 8p21.3-p22 is associated with progression of hepatocellular carcinoma
36. Frequent loss of heterozygosity on chromosomes 16 and 4 in human hepatocellular carcinoma
37. Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma
38. Loss of heterozygosity on chromosome 16 in hepatocellular carcinoma
39. Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma
40. Different pattern of chromosomal allele loss in multiple hepatocellular carcinomas as evidence of their multifocal origin
41. Deletion of the E-cadherin gene in hepatitis B virus-positive Chinese hepatocellular carcinomas
42. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China
43. Deletions in human chromosome arms 11p and 13q in primary hepatocellular carcinomas
44. Loss of somatic heterozygosity in hepatocellular carcinoma
45. Evidence for the presence of two tumour-suppressor genes for hepatocellular carcinoma on chromosome 13q
46. Frequent genetic alterations at the distal region of chromosome 1p in human hepatocellular carcinomas
47. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors
48. Loss of constitutional heterozygosity on chromosome 5q in hepatocellular carcinoma without cirrhosis
49. Détection quantitative semi-automatique des pertes d'hétérozygotie sur le bras long du chromosome 4 dans les carcinomes hépatocellulaires
50. Identification of homozygous deletions at chromosome 16q23 in Aflatoxin B1 exposed hepatocellular carcinoma
51. Loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in Taiwan
52. Comprehensive allelotyping of human hepatocellular carcinoma
53. Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype
54. Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1
55. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization
56. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization
57. Genomic aberrations in human hepatocellular carcinomas of differing etiologies
58. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity
59. Inactivation of p161NK4 in hepatocellular carcinoma
60. Deletions and rearrangements of the retinoblastoma gene in hepatocellular carcinoma, insulinoma and some neurogenic tumors as found in a study of 121 tumors
61. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1
62. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma
63. The p53 pathway
64. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa
65. Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas
66. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain
67. Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas
68. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan
69. p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand
70. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation
71. Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas
72. Mutational hotspot in the p53 gene in human hepatocellular carcinomas
73. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines
74. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: Association with tumor growth and invasiveness
75. p53 mutations in human hepatocellular carcinomas from Germany
76. Splicing mutations of the p53 gene in human hepatocellular carcinoma
77. Overexpression of p53: A rare event in a large series of white patients with hepatocellular carcinoma
78. Aberrations of p53 gene in human hepatocellular carcinoma from China
79. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas
80. Detection of aberrations of the p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis
81. p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese
82. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma
83. p53 gene mutation spectrum in hepatocellular carcinoma
84. Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma
85. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines
86. p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells
87. p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China
88. Mutation of p53 gene in hepatocellular carcinoma in Taiwan
89. Tumor-suppressor p53 gene in hepatitis C and B virus-associated human hepatocellular carcinoma
90. The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas
91. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation
92. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis
93. p53 mutations in british patients with hepatocellular carcinoma: Clustering in genetic hemochromatosis
94. p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation
95. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis
96. The Hedgehog and Writ signalling pathways in cancer
97. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas
98. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3
99. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity
100. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation
101. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection
102. Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma
103. Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas
104. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis
105. Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks
106. Amplification of the c-myc gene in human hepatocellular carcinoma: Biologic significance
107. Trisomy 1 and 8 occur frequently in hepatocellular carcinoma but not in liver cell adenoma and focal nodular hyperplasia. A fluorescence in situ hybridization study
108. Frequent multiplication of the long arm of chromosome 8 in hepatocellular carcinoma
109. The expression of c-myc and c-N-ras in human cirrhotic livers, hepatocellular carcinomas and liver tissue surrounding the tumors
110. Expression of ras and c-myc oncoproteins and hepatitis B surface antigen in human liver disease
111. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
112. The Pezcoller lecture: Cancer cell cycles revisited
113. The Rb/E2F pathway: Expanding roles and emerging paradigms
114. Deletions of chromosome 13q, mutations in retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma
115. Tumour suppressor p53 and Rb genes in human hepatocellular carcinoma
116. Loss of heterozygosity at chromosome 13q in hepatocellular carcinoma: Identification of three independent regions
117. Frequent k- ras -2 mutations and p16(INK4A)-methylation in hepatocellular carcinomas in workers exposed to vinyl chloride
118. p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma
119. p16 is a major inactivation target in hepatocellular carcinoma
120. High frequency of p16INK4A gene alterations in hepatocellular carcinoma
121. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population
122. p16INK4 gene mutation and allelic loss of chromosome 9p21-22 in Taiwanese hepatocellular carcinoma
123. Homozygous deletions of the CDKN2 gene and loss of heterozygosity of 9p in primary hepatocellular carcinoma
124. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas
125. Failure to detect genetic alteration of the mannose-6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) gene in hepatocellular carcinomas in Japan
126. Smad2 and Smad4 gene mutations in hepatocellular carcinoma
127. Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma
128. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing
129. A comparison of the molecular structure of integrated hepatitis B virus genomes in hepatocellular carcinoma cells and hepatocytes derived from the same patient
130. Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction
131. Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas
132. ras oncogene p21 expression in hepatocellular carcinoma
133. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth- suppression activity
134. Allelotype of colorectal carcinomas
135. Mutations of mitotic checkpoint genes in human cancers
136. Comprehensive allelotype study of hepatocellular carcinoma: Potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors
137. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma
138. Accumulation of genetic changes during development and progression of hepatocellular carcinoma: Loss of heterozygosity of chromosome arm 1p occurs at an early stage of hepatocarcinogenesis
139. Beta-catenin mutation and overexpression in hepatocellular carcinoma
140. Comparison between diploid and aneuploid hepatocellular carcinomas: A flow cytometric study
141. Relationship of nuclear DNA content to clinical and pathologic findings in patients with primary hepatic malignancy
142. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: Relationships with tumor grade, clinicopathologic parameters, and patients'survival
143. Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma
144. Expression profiling and identification of novel genes in hepatocellular carcinomas
145. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: Identification of genes involved in viral carcinogenesis and tumor progression